PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.
Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss ...
Opinion
COVID vaccine liability lawsuit dismissed by rubber-stamp judicial panel that botched law: lawyer
Neither trial nor appeals court seems to understand the procedure for "willful misconduct" claims under the PREP Act, says lawyer for estate of college student who died from COVID vaccine.
Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.
A rare clotting disorder puzzled doctors during the COVID vaccine rollout. New research reveals the unlikely chain of events ...
Add Yahoo as a preferred source to see more of our stories on Google. The Pfizer Covid vaccine increased the risk of heart problems for children sixfold in the first week of having the jab but led to ...
WASHINGTON (AP) — U.S. regulators approved updated COVID-19 shots Wednesday but limited their use for many Americans — and removed one of the two vaccines available for young children. The new shots ...
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of ...
Pfizer said today its COVID-19 vaccine has saved more than 14 million lives worldwide, after President Donald Trump urged pharmaceutical companies to justify the success of their pandemic drugs. In a ...
Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its COVID-19 vaccine will be sold for $110 to $130 per dose. This price model comes down to ...
NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results